Role of Lung Ultrasound and Pulsed-wave Doppler in Lung Consolidations in Mechanically Ventilated Patients
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Mar 31, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how lung ultrasound and a special type of blood flow measurement called pulsed-wave Doppler can help doctors better understand lung problems in patients who are on mechanical ventilation. Specifically, the trial looks at two conditions: atelectasis (when part of the lung collapses) and pneumonia (an infection in the lungs). The researchers want to see how the blood flow in the lungs changes in these conditions, which could help in managing the patients' care.
To participate in this trial, patients must be between the ages of 65 and 74 and currently receiving mechanical ventilation with visible lung consolidations on imaging tests like chest X-rays or CT scans. However, there are some exclusions, such as those who have been in other studies recently or have certain health issues that make participation unsafe. If eligible, participants can expect to undergo non-invasive lung ultrasound and blood flow measurements as part of their routine care. This study aims to improve how doctors assess and treat lung issues in critically ill patients, which could lead to better outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Under mechanical ventilation and presenting one or more consolidations on chest radiography or CT scan
- Exclusion Criteria:
- • Participation to another study
- • Poor echogenicity (morbid obesity, multiple thoracic dressings)
- • Contra-indications to superior limbs or torso mobilization
- • Contra-indications to bronchoscopy
- • Antibiotics initiated more than 24 hours but less than 72 hours before inclusion or changes in the antibiotic regimen in the last 72 hours.
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Martin Girard, MD, FRCPC
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials